Trimethadione

Summary

Trimethadione (CHEMBL695) is an approved small-molecule anticonvulsant (ATC N03AC02); indicated across 1 condition including epilepsy.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N03AC02
• Indications: 1 condition
• Chemistry: 143.14 Da · C6H9NO3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL695
Name	Trimethadione
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	5576
ChEBI	CHEBI:9727
ATC	N03AC02
Molecular formula	C6H9NO3
Molecular weight	143.14
InChIKey	IRYJRGCIQBGHIV-UHFFFAOYSA-N

SMILES: CC1(C(=O)N(C(=O)O1)C)C

IUPAC name: 3,5,5-trimethyl-1,3-oxazolidine-2,4-dione

ChEBI definition: An oxazolidinone that is 1,3-oxazolidine-2,4-dione substituted by methyl groups at positions 3, 5 and 5. It is an antiepileptic agent.

Pharmacological roles (ChEBI): geroprotector, anticonvulsant.

Also known as: A 2297, Absentol, Epidione, J2.519D, Minoaleviatin, NSC-15799, NSC-169503, Tridione, Tridone, Trimetadiona, Trimethadione, Trimethadionum

Patent coverage: 1,689 distinct patent families (6,067 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Prelamin-A/C.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
epilepsy	4	MONDO:0005027	EFO:0000474

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).